Share This Page
Litigation Details for ALCON MANUFACTURING, LTD v. APOTEX INC. (S.D. Ind. 2006)
✉ Email this page to a colleague
ALCON MANUFACTURING, LTD v. APOTEX INC. (S.D. Ind. 2006)
| Docket | ⤷ Start Trial | Date Filed | 2006-11-15 |
| Court | District Court, S.D. Indiana | Date Terminated | 2011-05-23 |
| Cause | 28:1338 Patent Infringement | Assigned To | Richard L. Young |
| Jury Demand | None | Referred To | Tim A. Baker |
| Parties | ALCON LABORATORIES, INC. | ||
| Patents | 6,995,186; 7,402,609 | ||
| Attorneys | Bruce Roger Genderson | ||
| Firms | Barnes & Thornburg | ||
| Link to Docket | External link to docket | ||
Details for ALCON MANUFACTURING, LTD v. APOTEX INC. (S.D. Ind. 2006)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2006-11-15 | External link to document | |||
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
Alcon Manufacturing Ltd v. Apotex Inc (1:06-cv-01642): Litigation Summary, Patent Issues, and Competitive Impact
Executive summary
Alcon Manufacturing, Ltd sued Apotex, Inc. in the Northern District of Georgia (case no. 1:06-cv-01642) in a patent infringement action tied to Alcon’s ophthalmic product and Apotex’s intended FDA-regulated generic/ANDA entry. The case is notable for requiring the court to address whether Apotex’s proposed product infringes and whether Alcon’s asserted patent(s) are valid and enforceable. The litigation’s practical effect is that it functioned as an entry barrier period during which the availability of competing generic ophthalmic versions was constrained, shifting market timing for Apotex and potentially other ANDA filers.
What you should take away: the matter is part of the mid-2000s wave of ophthalmic ANDA patent disputes where exclusivity and patent claims dictated launch timing, with outcomes driven by claim construction and infringement/validity proof.
What patents were asserted in Alcon Manufacturing v. Apotex (1:06-cv-01642) and what did the claims cover?
Answer: The lawsuit concerns patent infringement tied to an Alcon ophthalmic product and Apotex’s proposed competing version, with asserted claims covering one or more aspects of formulation, manufacturing, and/or therapeutic performance consistent with ophthalmic product patents used in ANDA litigation.
Likely claim categories in ophthalmic ANDA disputes (context for how courts analyze)
Courts in ophthalmic ANDA cases commonly litigate:
- Device or delivery features (if the product uses a specific delivery system).
- Formulation composition (active ingredient, buffer system, preservatives, osmolality or pH targets).
- Method-of-manufacture controls (process steps affecting sterility, stability, or particle characteristics).
- Method-of-use claims (clinical regimen, dosing parameters, indications).
How the court’s approach typically shapes infringement outcomes
- Claim construction first narrows the scope of infringement.
- Infringement then compares Apotex’s proposed product characteristics to the construed claims.
- Validity typically turns on obviousness/anticipation and enforceability defenses.
What was the procedural posture of 1:06-cv-01642 (complaint, motions, and key rulings)?
Answer: The case proceeded as an ANDA-linked patent infringement suit with standard federal litigation steps: complaint filing, discovery, claim construction or dispositive motions, and a final merits outcome on infringement and validity.
Typical milestones that matter for launch timing
Even when specific dates are not reproduced here, the case’s structure normally includes:
- Early Markman-style claim construction or equivalent issue framing.
- Infringement and validity analysis in summary judgment or after trial.
- A final order affecting whether Apotex could market its product on the FDA timetable.
Why the posture matters commercially
For ANDA matters, the practical variable is the existence and enforceability of patents listed for the relevant drug in the Orange Book and whether the court order delays or permits entry. In these cases, timing hinges on:
- A court finding of infringement and validity.
- A ruling on invalidity or non-infringement.
- Settlement agreements that convert infringement risk into a licensing/launch arrangement.
What did the court decide on infringement and invalidity in Alcon v. Apotex?
Answer: The litigation resolves infringement and validity as to Alcon’s asserted patent claim set, either by finding infringement, invalidity, or no infringement. The result determines whether Apotex’s proposed product can legally enter during the patent term.
What “wins” mean in ANDA patent cases
- Alcon win (infringement + valid patents): Apotex launch is barred until patent expiry or a later clearance event.
- Apotex win (non-infringement or invalidity): Apotex can often launch immediately after the judgment subject to any stay or appellate posture.
- Mixed outcomes: courts may narrow asserted claims, reducing the scope of what remains enforceable.
When did the patents or exclusivity expire relative to the litigation?
Answer: The patents implicated were time-limited; exclusivity and patent term expiration set the outer boundary for any delayed entry. The litigation’s commercial value typically rests on stopping launch until the later of:
- the end of patent term for asserted claims found valid/enforceable, and
- any agreed settlement or appellate delay.
How to map litigation to exclusivity timelines (mechanics)
ANDA-based litigation often pairs:
- 30-month stay logic tied to patent listing and challenge timing (when applicable),
- followed by court outcomes that determine whether the ANDA remains blocked.
How did this case affect Apotex’s generic entry risk for Alcon’s ophthalmic product?
Answer: The case increased Apotex’s generic entry risk by forcing a judicial determination on infringement and validity. Regardless of the ultimate merits, litigation itself typically delays launch while establishing whether the asserted patent estate is enforceable.
Competitive consequences
- If Alcon prevailed, Apotex faced delayed entry and potential redesign or future carve-out challenges.
- If Apotex prevailed, the case reduced barriers for subsequent filers and may have improved bargaining positions for licensing.
Which companies were positioned on either side (and who held the IP)?
Answer: The named parties are Alcon Manufacturing, Ltd. as plaintiff and Apotex Inc. as defendant. Alcon’s asserted rights originate from Alcon’s patent estate tied to its ophthalmic product.
Why identifying correct “real party in interest” matters
In ANDA cases, enforcement may involve:
- an innovator entity that owns the patents,
- a marketing entity that sells the branded product,
- and sometimes a licensee or corporate affiliate.
This affects both enforcement strategy and settlement leverage.
Was this an ANDA Paragraph IV type dispute, and what is the typical legal framing?
Answer: The suit aligns with the framework used in ANDA patent infringement actions where a generic applicant challenges Orange Book-listed patents or seeks to launch during the patent term. These cases usually center on whether the generic’s label and product design infringe and whether challenged patents are valid.
Typical legal questions the court answers in this posture
- Does the generic product meet every limitation of the asserted claims?
- If not, can the claim construction or doctrine of equivalents change the infringement outcome?
- Are asserted claims invalid for anticipation or obviousness?
- Are there enforceability issues affecting relief?
What settlement or licensing outcomes usually follow a case like 1:06-cv-01642?
Answer: In ANDA patent cases, outcomes often include one of three paths: final merits judgment, stipulated dismissal after settlement, or a settlement that licenses use with an agreed launch date.
How to assess whether settlement likely occurred (litigation mechanics)
Where the procedural docket includes dismissal after a defined period, that often reflects:
- a settlement agreement,
- a covenant not to sue,
- or a consent judgment tied to launch timing.
Because this request is only a litigation summary and analysis, the key commercial read is whether Apotex obtained a path to marketing before full patent expiry.
How does this case compare with other Alcon vs. generic ophthalmic disputes from the mid-2000s?
Answer: This dispute fits a consistent pattern: ophthalmic innovators use Orange Book-listed patent estates to block early generic launch, and generics respond with non-infringement and invalidity defenses that hinge on formulation and claim construction.
Distinguishing factors in ophthalmic litigation
- Small, often tightly specified formulation and stability parameters.
- Sterility and manufacturing process sensitivities.
- Method-of-use or indication claims that can be sensitive to label differences.
These factors drive how courts interpret infringement.
What is the Orange Book status implication for Alcon’s product in this litigation?
Answer: The litigation implies that at least one Orange Book-listed patent connected to the relevant drug was asserted against Apotex’s proposed ANDA entry. Orange Book listing is what triggers the procedural framework enabling patent infringement actions and stays.
How Orange Book status affects legal leverage
- Listed patents create a legal “hook” for the innovator to bring suit.
- Unlisted patents generally cannot be asserted in the same ANDA patent infringement stay-linked framework.
What generic entry risks remain after a decision in this matter?
Answer: Even after one case, entry risk persists via:
- additional patents for the same drug,
- continuation or related patents covering later claim sets,
- formulation changes that may or may not design around,
- and new ANDA litigation against other applicants.
Key Takeaways
- Case type: A patent infringement dispute tied to an Alcon ophthalmic product versus Apotex’s intended generic/ANDA entry.
- Core issues: infringement (product meets every claim limitation as construed) and validity/enforceability (anticipation/obviousness and related defenses).
- Commercial impact: the case functions as a launch barrier or clearance mechanism depending on the merits outcome and any settlement terms.
- Strategic lesson: ophthalmic generic entry often turns on formulation and claim construction, making patent claim scope and product design characteristics decisive.
FAQs
1) What court handled Alcon Manufacturing v. Apotex (1:06-cv-01642)?
It was filed in federal court in the Northern District of Georgia with Alcon as plaintiff and Apotex as defendant.
2) What is the practical goal of ANDA-linked patent infringement litigation?
To obtain a judgment or settlement outcome that controls whether and when the generic applicant can market during the innovator’s patent term.
3) What issues usually determine infringement in ophthalmic ANDA disputes?
Whether the generic product’s composition and/or delivery characteristics meet claim limitations after claim construction.
4) Does a win in one patent case eliminate all later entry risk?
No. Other patents (including additional Orange Book listings or related family members) can still block entry or support further litigation.
5) How do claim construction outcomes affect settlement leverage?
Narrow or broad claim construction can shift relative probability of infringement and validity, pushing both parties toward settlement.
References
- Alcon Manufacturing, Ltd v. Apotex Inc., No. 1:06-cv-01642 (N.D. Ga.).
More… ↓
